Laman Utama207940 • KRX
add
Samsung Biologics Co Ltd
Tutup sebelumnya
₩1,585,000.00
Julat hari
₩1,551,000.00 - ₩1,631,000.00
Julat tahun
₩982,000.00 - ₩1,987,000.00
Permodalan pasaran
71.94T KRW
Bilangan Purata
50.08K
Nisbah P/E
41.95
Hasil dividen
-
Dalam berita
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (KRW) | Dis 2025info | Perubahan T/T |
|---|---|---|
Hasil | 1.45T | 52.94% |
Perbelanjaan pengendalian | — | — |
Pendapatan bersih | — | — |
Margin untung bersih | — | — |
Pendapatan bagi setiap syer | 8.72K | 25.60% |
EBITDA | — | — |
Kadar cukai berkesan | — | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (KRW) | Dis 2025info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 1.46T | 12.13% |
Jumlah aset | 11.06T | -36.20% |
Jumlah liabiliti | 3.61T | -43.88% |
Jumlah ekuiti | 7.45T | — |
Syer tertunggak | 54.52J | — |
Harga kepada buku | 11.60 | — |
Pulangan pada aset | — | — |
Pulangan pada modal | — | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (KRW) | Dis 2025info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | — | — |
Tunai daripada operasi | — | — |
Tunai daripada pelaburan | — | — |
Tunai daripada pembiayaan | — | — |
Perubahan bersih dalam tunai | — | — |
Aliran tunai bebas | — | — |
Perihal
Samsung Biologics Co., Ltd. is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its core services range from late discovery to large-scale commercial manufacturing. The company focuses on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and mRNA vaccines.
The company has partnered with pharmaceutical companies such as Pfizer, GlaxoSmithKline, Eli Lilly, AstraZeneca and Bristol-Myers Squibb. Wikipedia
CEO
Diasaskan
2011
Tapak web
Pekerja
5,195
